Skip to main content

Lamisil Side Effects

Generic name: terbinafine

Medically reviewed by Last updated on Dec 14, 2023.

Note: This document contains side effect information about terbinafine. Some dosage forms listed on this page may not apply to the brand name Lamisil.

Applies to terbinafine: oral tablet.

Serious side effects of Lamisil

Along with its needed effects, terbinafine (the active ingredient contained in Lamisil) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking terbinafine:

More common

Less common


Incidence not known

Other side effects of Lamisil

Some side effects of terbinafine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to terbinafine: oral granule, oral tablet.


In general, side effects have been mild to moderate and transient; however, this drug has been associated with serious life-threatening events such as hepatic failure, anaphylaxis, and severe neutropenia. Unless otherwise specified, the listed side effects were reported with the tablets.[Ref]

Nervous system

Very common (10% or more): Headache (12.9%)

Common (1% to 10%): Taste disturbance/dysgeusia (including taste loss/ageusia), dizziness

Uncommon (0.1% to 1%): Hypogeusia, ageusia, paresthesia, hypoesthesia, tinnitus

Very rare (less than 0.01%): Vertigo, sedation, lightheadedness

Frequency not reported: Taste alteration

Postmarketing reports: Smell disturbance (including loss of smell), paresthesia, hypoesthesia, hearing impairment, hypoacusis, anosmia (including permanent anosmia), hyposmia[Ref]

Taste disturbances were typically noticed 5 to 8 weeks after starting therapy and returned to normal within several weeks after stopping the medication. The taste alteration has been rarely accompanied by a discoloration of the tongue and/or a disturbance in the sense of smell.

Hypogeusia (including ageusia) usually recovered within several weeks after this drug was stopped. Isolated cases of prolonged hypogeusia have been reported.

Taste disturbance (including taste loss), paresthesia, hypoesthesia, tinnitus, and vertigo have also been reported during postmarketing experience. Some cases of taste disturbance were severe enough to cause decreased food intake, weight loss, anxiety, and depressive symptoms.[Ref]


Very common (10% or more): Gastrointestinal symptoms, feeling of fullness, abdominal distension, diarrhea, dyspepsia/gastritis, nausea, abdominal pain, flatulence, vomiting, mild abdominal discomfort, abdominal cramps, belching

Common (1% to 10%): Upper abdominal pain

Uncommon (0.1% to 1%): Toothache

Very rare (less than 0.01%): Parotid swelling

Frequency not reported: Mild to moderate gastrointestinal discomfort, gastritis, gastric fullness, nausea and vomiting, discoloration of the tongue, hypogeusia, ageusia, metallic taste, severe sialadenitis

Postmarketing reports: Pancreatitis[Ref]

Vomiting, upper abdominal pain, and toothache have been reported with the oral granules. Vomiting has also been reported during postmarketing experience with the tablets.[Ref]


Very common (10% or more): Nonserious forms of skin reactions, rash, urticaria

Common (1% to 10%): Pruritus, erythema

Uncommon (0.1% to 1%): Photosensitivity reactions

Very rare (less than 0.01%): Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis), photosensitivity (e.g., photodermatosis, photosensitivity allergic reaction, polymorphic light eruption), alopecia/hair loss, psoriasiform eruptions or exacerbation of psoriasis, acute generalized exanthematous pustulosis, toxic skin eruption

Frequency not reported: Reversible alopecia areata of the scalp, pustular psoriasis, acrodermatitis continua of Hallopeau

Postmarketing reports: Serious skin reactions (e.g., drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome)[Ref]

An 81-year-old male who had been treated with topical antifungal agents for tinea pedis started this drug (125 mg orally daily) as the lesions did not respond to topical therapy. He was not taking any other medications and had no history of skin disease. No other skin lesions were observed at that time. Two weeks later, he developed erythematous and pustular lesions on his fingers and toes, and an erythematous macular eruption on the limbs. This drug was discontinued, but the eruptions continued to worsen. Histopathology of a punch biopsy from his toe showed intraepidermal sterile pustules containing neutrophils, so-called Kogoj's spongiform pustules. He was then diagnosed with having acrodermatitis continua of Hallopeau and was treated with corticosteroids therapy.

An 80-year-old female experienced DRESS secondary to severe sialadenitis coincident with this drug. The patient was admitted with a generalized pruriginous eruption. She presented with erythematous and edematous widespread confluent plaques, with a scaly annular border. She had initiated therapy 14 days before onset of the generalized rash, for a nonspecific squamous plaque of the trunk. DRESS induced by this drug was diagnosed and therapy was discontinued. Topical therapy was started with 0.5% clobetasol propionate cream applied to the whole body. The rash progressively improved and blood eosinophilia decreased.

A 68-year-old male experienced acute generalized exanthematous pustulosis coincident with this drug. He presented with a symmetrical maculopapular eruption on both lower anterior legs. Within 2 days, the rash generalized with facial involvement. He developed the rash 20 days after initiating oral therapy for onychomycosis. After withdrawal of this drug, the exanthema abated within 10 days under topical therapy with corticosteroids.

Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis), psoriasiform eruptions or exacerbation of psoriasis, acute generalized exanthematous pustulosis, hair loss, and photosensitivity reactions have also been reported during postmarketing experience.[Ref]


Very common (10% or more): Decreased appetite/anorexia

Frequency not reported: Hypoglycemia, decreased food intake (due to taste disturbance)[Ref]

Arthralgia and myalgia have also been reported during postmarketing experience.[Ref]


Very common (10% or more): Musculoskeletal reactions, arthralgia, myalgia

Very rare (less than 0.01%): Cutaneous and systemic lupus erythematosus

Postmarketing reports: Rhabdomyolysis, increased blood creatine phosphokinase, precipitation and exacerbation of cutaneous and systemic lupus erythematosus[Ref]


Common (1% to 10%): Liver enzyme abnormalities

Rare (0.01% to 0.1%): Serious liver dysfunction (including hepatic failure, increased hepatic enzymes, jaundice, cholestasis, liver decompensation, hepatitis), transient increases in liver enzymes, hepatobiliary dysfunction, cholestatic jaundice, liver failure (some cases leading to death or liver transplant)

Frequency not reported: Development of idiosyncratic and symptomatic hepatobiliary dysfunction, drug-induced autoimmune hepatitis

Postmarketing reports: Idiosyncratic and symptomatic hepatic injury[Ref]

Liver enzyme abnormalities (at least 2 times the upper limit of normal) have been reported in 3.3% of patients.

In most liver failure cases, patients had serious underlying systemic conditions; causal association with this drug was unclear.

A 57-year-old male with chronic hepatitis B virus (HBV) infection developed drug-induced acute autoimmune hepatitis coincident with this drug. He was given 250 mg once daily over a 12-week period for dermatophyte toenail onychomycosis. He developed the side effect just prior to completing the course of therapy. He was not taking any other drugs or herbal supplements, did not drink alcohol, and did not appear to suffer a flare of HBV infection. Liver function studies began to normalize 6 weeks after this drug was discontinued.

Cases of liver failure (some leading to death or liver transplant), hepatitis, cholestasis, and increased hepatic enzymes have also been reported during postmarketing experience.[Ref]


Common (1% to 10%): Depression

Very rare (less than 0.01%): Anxiety

Frequency not reported: Insomnia

Postmarketing reports: Anxiety (independent of taste disturbance), depressive symptoms (independent of taste disturbance), anxiety (secondary to taste disturbances), depressive symptoms (secondary to taste disturbances)[Ref]


Common (1% to 10%): Pyrexia, tiredness/fatigue

Uncommon (0.1% to 1%): Weight decreased

Rare (0.01% to 0.1%): Malaise (secondary to dysgeusia)

Very rare (less than 0.01%): Chest pain

Frequency not reported: Weight loss (due to taste disturbance), weight decreased (secondary to hypogeusia)

Postmarketing reports: Influenza-like illness

Pyrexia has been reported with the oral granules; it has also been reported during postmarketing experience with the tablets.

Malaise and fatigue have also been reported during postmarketing experience.


Common (1% to 10%): Nasopharyngitis, cough, upper respiratory tract infection, influenza, pharyngolaryngeal pain, rhinorrhea, nasal congestion

Nasopharyngitis, cough, upper respiratory tract infection, influenza, pharyngolaryngeal pain, rhinorrhea, and nasal congestion have been reported with the oral granules.


Changes in the ocular lens and retina have been reported; however, the clinical significance is unknown.

Dyschromatopsia, whereby the patient reported a greenish hue in her vision, and photopsia have occurred in a patient after 3 weeks of therapy. This problem resolved within 1 week of discontinuing the drug.[Ref]

Common (1% to 10%): Visual disturbance

Frequency not reported: Changes in ocular lens and retina, dyschromatopsia, photopsia

Postmarketing reports: Reduced visual acuity, visual field defect, blurred vision[Ref]


Agranulocytosis, thrombocytopenia, anemia, and pancytopenia have also been reported during postmarketing experience.[Ref]

Uncommon (0.1% to 1%): Anemia

Very rare (less than 0.01%): Neutropenia, agranulocytosis, thrombocytopenia, pancytopenia

Frequency not reported: Leukopenia, lymphopenia, transient decreases in hematocrit, transient decreases in hemoglobin, transient decreases in leukocytes

Postmarketing reports: Severe neutropenia, altered prothrombin time (prolonged and reduced) with concomitant warfarin[Ref]


Very rare (less than 0.01%): Anaphylactoid reactions (including angioedema)

Frequency not reported: Anaphylaxis, hypersensitivity reactions

Postmarketing reports: Serious hypersensitivity reactions (e.g., angioedema, allergic reactions [including anaphylaxis]), anaphylactic reaction, serum sickness-like reaction[Ref]


Frequency not reported: Renal function test impairment, transient increases in serum urea, transient increases in serum creatinine[Ref]


Frequency not reported: Hematuria, transient erectile dysfunction in male patients[Ref]


Postmarketing reports: Vasculitis

Frequently asked questions


1. Product Information. Lamisil (terbinafine). Sandoz Pharmaceuticals Corporation. 2001;PROD.

2. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol. 1992;126(suppl:61-9.

3. del Palacio Hernandez A, Lopez Gomez S, Gonzalez Lastra F, Moreno Palancar P, Iglesias Diez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol. 1990;15:210-6.

4. Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol. 1995;131:937-42.

5. Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents - terbinafine, fluconazole, and itraconazole. Int J Dermatol. 1998;37:410-5.

6. Beutler M, Hartmann K, Kuhn M, Gartmann J. Taste disorders and terbinafine. BMJ. 1993;307:26.

7. Ottervanger JP, Stricker BH. Loss of taste and terbinafine. Lancet. 1992;340:728.

8. Juhlin L. Loss of taste and terbinafine. Lancet. 1992;339:1483.

9. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]. Drugs. 1992;43:259-84.

10. Stricker BHC, Vanriemsdijk MM, Sturkenboom MCJM, Ottervanger JP. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol. 1996;42:313-8.

11. Abecassis S, Roujeau JC, Bocquet H, et al. Severe sialadenitis: a new complication of drug reaction with eosinophilia and systemic symptoms. J Am Acad Dermatol. 2004;51:827-30.

12. Rzany B, Mockenhaupt M, Gehring W, Schopf E. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol. 1994;30:509.

13. Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol. 1995;20:247-8.

14. Wach F, Stolz W, Hein R, Landthaler M. Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine. Arch Dermatol. 1995;131:960-1.

15. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol. 1994;74:391-2.

16. Condon CA, Downs AMR, Archer CB. Terbinafine-induced acute generalized exanthematous pustulosis. Br J Cancer. 1998;138:709-10.

17. Papa CA, Miller OF. Pustular psoriasiform eruption with leukocytosis associated with terbinafine. J Am Acad Dermatol. 1998;39:115-7.

18. Wilson NJE, Evans S. Severe pustular psoriasis provoked by oral terbinafine. Br J Dermatol. 1998;139:168.

19. Bennett ML, Jorizzo JL, White WL. Generalized pustular eruptions associated with oral terbinafine. Int J Dermatol. 1999;38:596-600.

20. Bonsmann G, Schiller M, Luger TA, Stander S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2001;44:925-31.

21. Nishiwaki F, Matsumura Y, Morita N, Kore-Eda S, Miyachi Y, Omoto M. Acrodermatitis continua of Hallopeau due to oral terbinafine. Br J Dermatol. 2007;157:1073-4.

22. Verros CD, Rallis E. The role of terbinafine in induction and/or exacerbation of psoriasis. Int J Dermatol. 2012;52:1155-6.

23. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. BMJ. 1993;306:248.

24. Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC. Terbinafine-induced cholestatic liver disease. J Hepatol. 1996;24:753-6.

25. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: Case report and review of the literature. Am J Gastroenterol. 1998;93:459-60.

26. Gupta AK, DelRosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol. 1998;23:64-7.

27. Itracanazole, terbinafine possibly linked to liver failure. Am J Health Syst Pharm. 2001;58:1076.

28. Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother. 2007;41:880-4.

29. Cerner Multum, Inc. UK Summary of Product Characteristics.

30. Gupta AK, Gonder JR, Shear NH, Dilworth GR. The development of green vision in association with terbinafine therapy. Arch Dermatol. 1996;132:845-6.

31. Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol. 1994;31:806.

32. Gupta AK, Soori GS, DelRosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol. 1998;38:765-7.

33. Grunwald MH, Amichai B. Thrombocytopenia associated with oral terbinafine. Int J Dermatol. 1998;37:634.

34. Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. Br J Dermatol. 1999;140:1196-7.

35. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA. Australian Adverse Drug Reactions Bulletin. 2007.

36. Gupta AK, Kopstein JB, Shear NH. Hypersensitivity reaction to terbinafine. J Am Acad Dermatol. 1997;36:1018-9.

37. Beltraminelli HS, Lerch M, Arnold A, Bircher AJ, Haeusermann P. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005;152:780-3.

38. Rossetti G, Livio F, Roulet E, Hofer MF. Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine. Pediatr Allergy Immunol. 2005;16:453-5.

39. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992;126 Suppl:51-5.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.